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Objective: A central role of macrophages in initiating lung ischemia-reperfusion
injury is emerging. Tumor necrosis factor- is a proinflammatory cytokine secreted
mainly by macrophages under various conditions. We hypothesized that tumor
necrosis factor- from resident lung cells is a key initiating factor in pulmonary
ischemia-reperfusion injury.
Methods: We used an isolated, buffer-perfused lung system to explore the role of
tumor necrosis factor- production by resident lung cells in pulmonary ischemia-
reperfusion injury. Lungs from wild-type mice and tumor necrosis factor-–defi-
cient mice were subjected to 60 minutes of ischemia followed by 60 minutes of
reperfusion. Histologic injury scores and measurements of lung compliance, airway
resistance, mean pulmonary artery pressure, vascular reactivity, and wet lung weight
index were obtained and compared using repeated-measures analysis of variance.
Results: Lungs from tumor necrosis factor-–deficient mice showed significantly
less injury in all physiologic parameters throughout the entire 60 minutes of
reperfusion compared with lungs from wild-type mice (P .001). The most notable
effects were observed in pulmonary artery pressure and airway resistance. Vascular
reactivity (acute vasoconstrictive episodes per 60 minutes) was also blunted in the
lungs from tumor necrosis factor-–deficient mice compared with the lungs from
wild-type mice (5.8 responses/hour vs 1.2 responses). Histologic injury scores and
wet lung weight index were significantly reduced in lungs from tumor necrosis
factor-–deficient mice.
Conclusions: By using the advantages of a nonblood-perfused system, we have
focused our investigation on resident lung cells. Our results demonstrate that
resident cell-produced tumor necrosis factor- is a key initiating factor in acute lung
ischemia-reperfusion injury.
Our group and others have demonstrated that lung ischemia-reper-fusion (I/R) injury is complex and that it involves many systems,for example, the release of oxygen radicals, xanthine-oxidasesystem, leukocyte adhesion and rolling factors, and activation ofneutrophils and alveolar macrophages.1-6 The complement systemhas also been implicated, in which both the formation of mem-
brane attach complex and generation of the anaphylatoxin C5a can contribute to I/R
injury.7 There is increasing evidence indicating that tumor necrosis factor (TNF)-
is an initiating factor in many of these processes and is required to produce the
pathophysiology in lungs subjected to different inflammatory models and endotoxin
shock.8-10
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TNF- is a 17-kDa proinflammatory cytokine predomi-
nantly secreted by macrophages in response to a variety of
pathologic processes. Investigators have demonstrated that
TNF- compromises the endothelial barrier and produces
experimental pulmonary edema.11,12 TNF-, as well as
other proinflammatory cytokines, has been detected in the
bronchoalveolar lavage fluid obtained from patients with
acute respiratory distress syndrome13 and has been shown to
increase pulmonary vascular resistance, resulting in alveolar
edema because of the release of thromboxane A2 in re-
sponse to activation of polymorphonuclear leukocytes.12
TNF- also increases the neutrophil population in the lung
caused by inducing endothelium-derived polymorphonu-
clear chemotactic and adherent factors.14
TNF- may function as the initial cytokine in the com-
plex inflammatory cascade observed in lung I/R injury.
Previous studies have been unable to completely isolate
specific components of pulmonary I/R injury; thus it has
been difficult to focus on single components of this complex
cascade. The main objective of this project was to investi-
gate the role of resident lung cells (most likely macro-
phages) and TNF- secreted by these cells in pulmonary I/R
injury. Our hypothesis is that TNF- from resident lung
cells is a key initiating factor in pulmonary I/R injury.
Methods
Study Design
By use of an isolated lung system, lungs from male wild-type
(WT) C57BL6 mice (n 8) and male mice deficient in the TNF-
gene (TNF/) (n  8) were subjected to 60 minutes of pulmo-
nary ischemia followed by 60 minutes of reperfusion with Krebs-
Henseleit buffer. As a control, the WT sham group received 120
minutes of reperfusion without ischemia. To minimize any inher-
ent variability between groups, the animals used in all groups
(25-30 g body weight) were born within the same week and housed
in the same vivarium. Hemodynamic and pulmonary parameters,
as well as histologic grading scores, were compared between the 2
groups throughout the reperfusion period.
Animal acquisition was under the supervision of the Depart-
ment of Comparative Medicine and a licensed veterinarian. All
animals received humane care in compliance with the “Principles
of Laboratory Animal Care,” formulated by the National Society
for Medical Research, and “The Guide for the Care and Use of
Laboratory Animals,” prepared by the National Academy of Sci-
ence and published by the National Institutes of Health (publica-
tion 85-23, revised 1985).
Isolated, Perfused Lung Model
For this study, we used an isolated, perfused mouse lung system
(Hugo Sachs Elektronik, March-Huggstetten, Germany). Mice
were anesthetized with ketamine and xylazine. A tracheostomy
was performed, and animals were ventilated with room air at 100
breaths/min and a tidal volume of 15 mL/kg body weight with a
positive end-expiratory pressure of 2 cm H2O. A midline abdom-
inal incision was made, and the inferior vena cava was cannulated
with a 30G needle and injected with 50 units of heparin. The
animals were exsanguinated by inferior caval transection. The
subdiaphragmatic portion of the animal was excised and discarded.
The anterior chest plate was removed, exposing the lungs and
heart. With the use of an operating microscope, the thymus was
dissected cephalad exposing the great vessels. A 4-0 silk suture
was passed behind the pulmonary artery (PA) and aortic root. A
partial half-knot was created with the suture, leaving room for a
cannula to be passed into the PA. A small curvilinear incision was
made in the right ventricular outflow tract with the perfusate
flowing at 0.6 mL/min, and the PA cannula was passed under
direct vision through the pulmonary valve and into the main PA.
The left ventricle was immediately vented with a small incision at
the apex of the heart. The mitral apparatus was carefully dilated,
and the left atrial cannula was passed through the mitral valve and
into the left atrium. The placement of the PA and left atrial cannula
was further confirmed by a pressure tracing generated by the
PULMODYN data acquisition system (Hugo Sachs Elektronik).
The lungs were then perfused at a constant flow of 2 mL/min with
Krebs-Henseleit buffer containing 2% albumin, 0.1% glucose, and
0.3% HEPES (335-340 mOsm/kg). The Krebs solution was pre-
pared to mimic mixed venous blood using a gas bubbling stone
with titrated gases generating a pH of 7.40 to 7.45, a PO2 of 60 to
70 mm Hg, and a PCO2 of 50 to 60 mm Hg. The buffered perfusate
and isolated lung apparatus were maintained at 37°C.
All lungs were allowed to equilibrate during a 10-minute sta-
bilization period. After equilibration, the ventilation rate was de-
creased to 50 breaths/min, and the fraction of inspired oxygen was
decreased to less than 1%. To initiate the ischemic period, hypoxic
ventilation was maintained with 95% nitrogen and 5% carbon
dioxide gas, and perfusion was arrested. After 60 minutes of
ischemia and hypoxic ventilation, the perfusion and room air
ventilation were resumed, initiating the reperfusion period. Left
atrial efflux was collected at 1-minute intervals for the first 5
minutes of reperfusion and then every 15 minutes thereafter for the
entire 1-hour period of reperfusion.
Hemodynamic and Pulmonary Parameters
PA pressure (PAP), pulmonary venous (left atrial) pressure, airway
resistance (AR), peak airway pressure, and pulmonary compliance
were continuously measured, recorded, and stored by the
PULMODYN W software system (Hugo Sachs Elektronik). All of
the system’s transducers were designed and selected specifically
for the parameters to be measured. For measurement of vascular
pressures, a transducer with a limited pressure range (P75; pressure
range 75 mm Hg) was used to obtain sensitive and accurate
measurement of venous pressures. A separate low-pressure trans-
ducer (pressure range 100 cm H2O) was used to measure air
pressures within the airway (using an optional pneumotachometer
with a pressure side port). The integrated pneumotachometer and
matched differential pressure transducer were designed specifi-
cally to measure respiratory airflow from the mouse lung. AR
(dynamic resistance) is defined as “delta pressure” divided by
“delta flow.” To calculate resistance, PULMODYN takes the cor-
responding pleural pressure (or esophageal pressure) values and
pulmonary flow values at 70% of the amplitude in the tidal volume
signal to calculate the “delta pressure” and “delta flow.” Pulmo-
nary compliance is defined as “delta volume” divided by “delta
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pressure.” To calculate compliance, PULMODYN takes the cor-
responding tidal volume values and pleural pressure values (or
esophageal pressures) at the zero points of the flow signal to
calculate the “delta volume” and “delta pressure.”
Lung Weight Index
At the completion of reperfusion, the mediastinal structures were
removed en bloc, and the lungs were individually weighed. This
weight was then divided by the preprocedure weight of the mouse
to obtain the lung weight index (LWI).
Lung Injury Score
After the lung weight was obtained, the right lower lobe was fixed
in 10% buffered formalin and embedded in paraffin. Slides were
stained with hematoxylin-eosin and examined by a pulmonary
pathologist blinded to animal group. Lung tissue was graded by the
presence or absence of interstitial infiltrate, intra-alveolar fibrin,
and alveolar integrity, providing a total injury score of 0 to 3 (0 
no injury, 3  severely injured).
Statistical Analysis
Data are presented as mean  SEM. Analysis of variance
(ANOVA) was used to determine whether significant differences
existed between groups. Two-way repeated-measures ANOVA




The detrimental effects of TNF- were clearly exhibited in
every parameter measured during reperfusion. The most
notable differences were those relating to pulmonary
edema. Severe edema resulted in the failure to complete 60
minutes of reperfusion in 4 WT animals exposed to I/R (not
included in the study) because the perfusate was pulled into
the ventilator, forcing termination of the experiment. This
observation was not observed in TNF/ mice.
Figure 1 shows the increased endothelial leakage and
subsequent pulmonary edema observed after I/R. Although
individual lung weights were always greater in the right
lung than the left, the relationship remained consistent. The
LWI after I/R was 19.3% greater in the WT lungs (14.2 
0.3) compared with the TNF/ lungs (11.9  0.3, P 
.05). Again, this was very notable at the gross level because
the WT lungs subjected to I/R frequently leaked perfusate
during the reperfusion period. The LWIs in both WT and
TNF/ lungs subjected to I/R were significantly higher
than in the WT sham lungs subjected to the same perfusion
protocol without ischemia.
Mean PAP
Mean PAP was significantly reduced in TNF/ lungs
subjected to I/R throughout the reperfusion period (Figure
2) compared with WT lungs subjected to I/R. Interestingly,
this difference was noted at the onset of reperfusion when
the WT lungs subjected to I/R were profoundly hyperten-
sive immediately on reperfusion. PAP in all groups, before
ischemia, was not different, ranging from 8 to 10 cm H2O.
Subtle increases in mean PAP were observed in the
TNF/ lungs after 40 minutes, but these did not reach
even half the increases seen in the WT lungs subjected to
I/R. The cumulative effect observed in the PAP tracing is
the result of acute vasoconstrictive responses observed
throughout the 60-minute reperfusion period. These hyper-
tensive spikes were observed frequently in the WT lungs
subjected to I/R (5.8 responses/hour) versus the TNF/
lungs subjected to I/R (1.2 responses/hour), with PAP in-
creasing 2-fold for periods of 1 to 3 minutes before a return
to baseline. These vascular response spikes resembled those
seen in hypoxic pulmonary vasoconstrictive models, yet
there was no hypoxia during the reperfusion period when
these episodes were observed.
AR
AR, unlike PAP, was similar between all groups at the
initial stage of reperfusion, ranging from 0.8 to 0.9 cm H2O
· L · sec (Figure 3). At 30 minutes of reperfusion, an
approximate doubling of AR was observed in the WT lungs
subjected to I/R, and at 60 minutes the AR was 4 times
greater in the WT lungs subjected to I/R compared with the
TNF/ lungs subjected to I/R (P .05). This finding may
indicate the effects of TNF- extending beyond the level of
the pulmonary vasculature to that of the bronchial epithe-
lium, causing bronchoconstriction.
Pulmonary Compliance
Pulmonary compliance is one of the most significant clinical
indicators of reperfusion injury. Figure 4 illustrates the
change in pulmonary compliance observed during reperfu-
sion. The TNF/ lungs subjected to I/R demonstrated
significantly improved compliance throughout the entire
Figure 1. LWI after reperfusion (*P < .05 vs all, #P < .05 vs WT
sham). WT, Wild-type; TNF/, tumor necrosis factor- defi-
cient; I/R, ischemia-reperfusion; LWI, lung weight index.
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reperfusion period compared with the WT lungs subjected
to I/R. The WT lungs subjected to I/R, however, demon-
strated diminished compliance as early as 20 minutes, and at
50 minutes compliance was 38% less than in the TNF/
lungs subjected to I/R. Pulmonary compliance in all groups,
before ischemia, was not different, ranging from 21 to 24
L/cm H2O.
Histologic Grading of Lung Injury
Table 1 illustrates the histologic grading of pulmonary
injury after 60 minutes of reperfusion. The WT lungs ex-
posed to I/R demonstrated a more than double histologic
injury score (2.00  0.17) compared with the TNF/
lungs exposed to I/R (0.86  0.26, P  .001). Notably, the
TNF/ lungs demonstrated no more significant injury
Figure 2. Mean PAP during 60 minutes of reperfusion (*P < .05 using 2-way repeated-measures ANOVA). WT,
Wild-type; TNF/, tumor necrosis factor- deficient; I/R, ischemia-reperfusion; PAP, pulmonary artery pressure.
Figure 3. AR during 60 minutes of reperfusion (*P < .05 using 2-way repeated-measures ANOVA). WT, Wild-type;
TNF/, tumor necrosis factor- deficient; I/R, ischemia-reperfusion.
Figure 4. Pulmonary compliance during 60 minutes of reperfusion (*P < .05 using 2-way repeated-measures
ANOVA). WT, Wild-type; TNF/, tumor necrosis factor- deficient; I/R, ischemia-reperfusion.
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than that observed in the WT sham lungs subjected to
perfusion but no ischemia.
Discussion
The multifaceted phenomenon of I/R involves many com-
ponents, including alveolar macrophages, vascular endothe-
lial cells, circulating neutrophils, adhesion factors, free rad-
icals, complement, and a wealth of cytokines such as
TNF-. Our group and others have attempted to better
understand and describe some of the components of this
process. The complexity and amplification of the cascades
involved in this phenomenon, however, have made investi-
gation of individual components of reperfusion injury dif-
ficult to assess.
There is a large body of literature describing techniques
to attenuate lung I/R injury; however, little attention is
focused on the specific mechanisms of lung I/R injury itself.
In particular, characterization of the injury pattern during
the early phase of reperfusion is very limited. Our group has
recently described the biphasic nature of reperfusion injury
after lung transplantation, beginning with a resident (donor)
macrophage response followed by a more intense response
by circulating (recipient) neutrophils.3
Neutrophils have long been recognized as a critical com-
ponent of the inflammatory cascade, yet their role in lung
I/R injury has been a source of controversy. Evidence that
circulating neutrophils play an important role in lung I/R
injury has been suggested by investigators using leukocyte
depletion techniques and antibodies directed toward adhe-
sion molecules.1,9,15 In contrast, some investigators have
demonstrated that significant I/R injury can occur without
neutrophil participation and that neutrophils may have no
effect at all in some models of lung injury.16 Because of the
discrepancies regarding the role of neutrophils in lung I/R
injury, we used a model that eliminated the role of circu-
lating neutrophils altogether and that allowed us to focus
strictly on resident cells in the lung.
The goal of this project was to establish a working model
of lung I/R in a nonblood-perfused system. We developed a
novel technique of evaluating I/R in an isolated murine lung
system and investigated its unique advantages using oxy-
genated buffer (not blood) during reperfusion. The advan-
tages of this system are 3-fold: (1) A pH-balanced, buffered
solution completely eliminates the roll of circulating cells in
the acute response of reperfusion injury; (2) a nonblood-
perfused system eliminates the need for large quantities of
blood to prime the reperfusion pump; and (3), most impor-
tant, this system allows us to explore more in-depth cellular
and molecular mechanisms by using various genetic mouse
models.
The oxygen supply to cells and tissues is pivotal in
maintaining their function and integrity. I/R injury, how-
ever, is not totally dependent on ischemic time. I/R injury is
a paradoxical increase in tissue injury during the reperfusion
period in an organ that has sustained relatively minor dam-
age during a period of ischemia.17 Atochina and col-
leagues18 have convincingly demonstrated that pulmonary
tissue oxygenation can occur through pulmonary vascula-
ture or alveolar oxygen diffusion. Lung ischemia does not
necessarily lead to tissue anoxia, and reperfusion does not
mean reoxygenation if ventilation is maintained throughout
the ischemic period. Clinically, this principal is applied
during cardiopulmonary bypass to avoid reperfusion injury
because ventilation of the pulmonary tissue is maintained
despite cardiopulmonary arrest. In the present study, we
used an isolated murine lung system ventilated with 95%
nitrogen and 5% carbon dioxide during the ischemic period.
The technique of constant ventilation with hypoxic gas
allowed us to avoid the possible effects of reoxygenation
injury associated with atelectatic lung tissue and instead
focus on reperfusion injury.
Serrano and colleagues19 showed that TNF- enhances
intercellular adhesion molecule-1, E-selectin, and vascular
cell adhesion molecule-1 expression in human aortic endo-
thelial cell monolayers. Ferro and colleagues20 showed that
a 4-hour incubation with TNF- reduces PA endothelial
monolayer selectivity by a nitric oxide-dependent mecha-
nism. However, the studies that evaluate cytokine involve-
ment in producing lung damage usually require 3 to 4 hours
before the endothelial barrier damage is present in measur-
able amounts. Even when TNF- is administered to animals
or placed into bathing solutions surrounding endothelial cell
monolayers, 3 to 4 hours are required before monolayer
damage and the cell up-regulation of adhesion and rolling
factors occur.13,18 Previous studies with I/R models of iso-
lated rat lungs used much shorter periods of ischemia (45
minutes-1 hour) followed by 1 to 2 hours of reperfusion.
Eppinger and colleagues9 recently published data demon-
strating an increase in TNF- mRNA expression in rat lungs
subjected to 1.5 hours of ischemia and only 30 minutes of
reperfusion. From these data, we hypothesized that TNF-
is involved in even the most acute stages of pulmonary
reperfusion injury.
Leukocyte trafficking into sites of inflammation is
largely directed by cytokines. The presence of cytokine
gene expression or protein during I/R injury has been shown
TABLE 1. Histologic lung injury score after reperfusion
Group Lung injury score*
WT sham 0.67 0.21
WT I/R 2.00 0.17†
TNF/ I/R 0.86 0.26
WT, Wild-type; TNF/, tumor necrosis factor- gene knockout mice; I/R,
ischemia-reperfusion.
*Scale: 0  no injury, 3  severely injured.
†P  .001 versus all.
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in several model systems.9 The role of specific cytokines
such as TNF- in mediating leukocyte populations in lungs
subjected to I/R has not been defined. The role that TNF-
plays in I/R injury in the present study is unique from other
published data. We propose that the effect of TNF- in
pulmonary I/R injury is beyond neutrophil recruitment into
previously ischemic tissue. Our isolated, nonblood-perfused
model has demonstrated a direct negative effect on pulmo-
nary vascular endothelium and alveolar wall structure with-
out any participation from circulating cells.
Although the pathophysiology of I/R injury in the lung is
not completely understood, loss of normal endothelial func-
tion and integrity seems to play a pivotal role.21 Our use of
a blinded pulmonary pathologist in attaining lung injury
scores provided interesting results. The scoring system our
group previously used for quantifying lung injury22 required
modification in this study because of the lack of neutrophil
infiltration that would normally be observed in injured or
reperfused lung tissue. Light microscopy demonstrated di-
minished perivascular edema and alveolar destruction in
TNF/ lungs exposed to anoxic ventilation followed by
reperfusion and oxygenation compared with the same insult
on WT lungs. This histologic finding was grossly mani-
fested in lung weight indices and physiologically character-
ized by decreased pulmonary compliance and increased
mean airway pressures in WT lungs subjected to I/R com-
pared with TNF/ lungs exposed to I/R.
Vascular endothelium is a predominant cellular source of
oxidants associated with lung I/R injury. The role of resi-
dent lung cells such as macrophages, however, is not fully
understood and may have a more predominant role than
previously believed in lung I/R injury. Macrophages are
pivotal cells in the production of a variety of cytokines,
especially TNF-. In addition, macrophages express recep-
tors on their surface, which allows them to act as target cells
for cytokines.
We used novel technology in the investigation of pul-
monary I/R injury. Our study demonstrates the application
of an isolated, nonblood-perfused murine system to inves-
tigate very specific components of a complex physiologic
process. Our data demonstrate that TNF- from resident
lung cells is a key initiating factor in pulmonary I/R injury.
The source of this TNF- has not been established, but it
may likely arise from resident lung macrophages. These
findings have important clinical implications in areas of
lung transplantation and cardiopulmonary bypass surgery.
For example, these results indicate that anti-TNF- therapy
directly to the donor lung before transplantation may sig-
nificantly blunt the initiation of acute I/R injury that is
observed in many patients posttransplantation.
We express our appreciation to Dr Mark Stoler for histologic
evaluation of lung sections and to Kim Shockey for statistical
analysis.
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Discussion
Dr G. Alexander Patterson (St Louis, Mo). Does this model
use a 1-hour period of ischemia?
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Dr Maxey. That is correct. We begin with a 10-minute stabi-
lization period after hemorrhage in which the buffer is simply
perfused through the pulmonary circuit. To begin the experiment,
the lungs are no longer perfused, the buffer is simply turned off,
and I control the ventilatory status and can make them hypoxic or
normoxic.
Dr Patterson. I would like your comments about this. One of
the problems with all these reperfusion studies or I/R injury studies
is the model. Is the model too extreme? You showed some differ-
ences, but there were some areas in which there really was not a
whole lot of difference. Is the model too severe to answer the
question that you pose? Do you have any data from a shorter
period of ischemia?
Dr Maxey. We are currently working on a methods article to
describe this new technique. This is a novel technique, and we are
one of the first groups using this model. We do have some data. If
I can have my slides to further demonstrate the model.
(Slide) Nitrotyrosine staining. This is a stain that is fairly
nonspecific but is a marker of oxidative injury. One slide shows the
sham animals that did not undergo an ischemic period before the
perfusion. The other slide demonstrates marked oxidative injury of
the endothelium. So the injury we are seeing is oxidative in nature,
consistent with reperfusion, but we are currently working on a
grading system that will more accurately define the injury after 15
and 30 minutes of ischemia.
Dr Jakob Vinten-Johansen (Atlanta, Ga). That is a very nice
study. How did you ascertain that the TNF- was in fact derived
from macrophages because tissue itself can release inflammatory
mediators?
Have you used, for example, an antagonist or receptor type-1 to
double-check the role of TNF-?
What is the connection between TNF- and oxidant-mediated
injury in a cell-free environment such as this?
Dr Maxey. Those are certainly very good and important ques-
tions, especially for a new model.
The TNF- oxidant injury that I think we are seeing for this
particular model is related to the effects of TNF weakening the
endothelium. With a weakened endothelial barrier, most of the
results that we have seen are probably related to pulmonary edema.
We are currently investigating the peripheral effects of TNF,
particularly its role in bronchoconstriction. I believe the damage
observed in this model is TNF mediated and results in endothelial
destruction and then pulmonary edema.
As far as studies using antibodies or blockers to further define
the role of TNF, this model does have some limitations. This new
technique involves an asanguinous model. If we pretreat the ani-
mals with a TNF antibody and then the animals are exsanguinated,
the role of that particular antibody would be difficult to correctly
define.
On the other hand, we can take the antibody and put it in the
buffer and perfuse the pulmonary circuit with this antibody, but
again, I am not sure the buffer and antibody would reach the
interstitial macrophages. We are, however, currently working on
methods to better define this particular model. We have recently
used macrophage inhibitors with hopes to mimic these results as
well.
As far as the TNF-macrophage connection, true, other cells do
secrete TNF-, but they are mostly circulating cells, and again, we
have eliminated the role of circulating cells in this particular
model. So whatever is making TNF (we will assume that it is the
resident macrophages for the purpose of this study), it is certainly
present in the lung tissue. Again, this model involves no circula-
tory cells whatsoever. So the resident cells within the lung, par-
ticularly pulmonary macrophages, are the main secretors of TNF.
Dr Frank W. Sellke (Boston, Mass). I will go back to that
point. In the heart and other organs, parenchymal tissue actually
produces most of the TNF. You can perform immunohistochem-
istry to determine the actual location of TNF in your model. Also,
have you looked at other cytokines, for example, interleukin (IL)-2
and IL-6, to see if you see the same effects or is this specific for
TNF-?
Dr Maxey. We have looked at the role of IL-1, which seems to
mimic the TNF results. However, our data with IL-1 and other
cytokines are not yet complete. We are currently studying the
bronchoalveolar lavage fluid and hope to publish more complete
data correlating lavage fluid cytokine concentrations with direct
physiologic changes observed during reperfusion.
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